On July 31, 2019, the Board of Directors of Pieris Pharmaceuticals, Inc., following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Maya Said, Sc.D., to the Board to serve as a Class II Director with a term expiring at the Company’s 2022 annual meeting of stockholders. Dr. Said was also appointed to serve on the Nominating and Corporate Governance Committee and Science and Technology Committee of the Board. Dr. Said is the Founder and Chief Executive Officer of Outcomes4Me Inc., a health technology company focused on providing patients diagnosed with cancer and other chronic life altering diseases with personalized treatment options as well as outcomes information. She served as the Chief Operating Officer of Celsius Therapeutics, where she established and managed the company’s operations from inception through the company’s first year post-launch. Before founding Outcomes4Me, Dr. Said was Senior Vice President, Global Head of Oncology Policy & Market Access at Novartis, where she defined Novartis’ oncology franchise value and pricing strategy to address pricing pressures and established global pricing guidance for numerous oncology products. Her previous experience also includes a senior position at Sanofi, where she served as Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D, and at Boston Consulting Group, where she most recently served as a Principal. She currently serves on the Board of Transgene.